As the SCOPE Summit unfolds over the coming days, a steady stream of announcements is shaping how clinical research teams think about feasibility, enrollment, and execution. These are not abstract discussions. They are practical responses to long-standing friction points in trial design that slow studies down and distance protocols from the realities of patient access.
One of the early signals to watch comes from PhaseV, which used the opening of the meeting to introduce its new AI-powered Enrollment Lab. The launch reflects a broader shift visible across SCOPE this year. Sponsors and CROs are moving upstream, earlier in the development lifecycle, to replace assumption-driven planning with evidence-grounded decision-making.
Enrollment remains one of the most persistent causes of trial delay. Protocols are often finalized before teams fully understand how inclusion and exclusion criteria interact with real world patient availability or with competitive trial pressure. PhaseV’s Enrollment Lab is designed to address that gap by allowing study teams to quantify true enrollment potential before protocol lock, not after sites have already struggled.
Built as a high impact extension of the PhaseV ClinOps platform, the Enrollment Lab leverages real world EHR data to model patient eligibility alongside patient level competition. Instead of relying on theoretical projections or late stage site surveys, sponsors can explore how specific protocol trade offs affect enrollment volume in real time. Small design decisions become visible for what they are, either barriers to access or opportunities to expand reach.
Raviv Pryluk, PhD, CEO and co-founder of PhaseV, described the intent as a shift from planning on paper to planning in clinical reality. By uncovering constraints early, teams can stress test their designs and ensure that studies are grounded in a verified patient population before site identification begins. That change in timing matters. It moves feasibility from a reactive step to a strategic one.
From a technical perspective, the Enrollment Lab extends PhaseV’s population first approach. Elad Berkman, CTO and co founder, emphasized the ability to translate protocol choices and competitive pressure into a clear view of real patient access. This precision guided modeling allows teams to evaluate alternative inclusion criteria, identify lightly contested patient segments, and surface geographic regions that may be overlooked by traditional planning methods.
Positioned early in the workflow, the Enrollment Lab establishes what is realistically achievable before resources are committed downstream. Once realistic enrollment potential is defined, PhaseV’s site identification tools can then prioritize investigators based on their ability to deliver against that plan rather than aspirational targets. The result is tighter alignment between protocol design, site selection, and execution.
As conversations continue throughout SCOPE, this launch is likely to gain strong traction among sponsors focused on shortening timelines without compromising scientific rigor. The message aligns with what many leaders here are emphasizing. Faster trials do not come from pushing sites harder. They come from designing studies that reflect how patients actually exist within health systems.
PhaseV is demonstrating the Enrollment Lab throughout the Summit, offering attendees a closer look at how real world data can be applied before the first site is ever activated. For an industry increasingly focused on predictability and patient centricity, this announcement sets an early tone for the news still to come out of SCOPE in the days ahead.
